Eine doppelblinde, placebokontrollierte Phase-3-Studie (Teil A) mit einer offenen Erweiterung (Teil B) zur Bewertung von MM120 im Vergleich zu Placebo bei generalisierter Angststörung
Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte, 12-wöchige Phase-3-Studie (Teil A) mit einer 40-wöchigen offenen Verlängerung (Teil B) zur Bewertung der Wirksamkeit und Sicherheit von oralem MM120 im Vergleich zu Placebo in der Studie Behandlung von Erwachsenen mit generalisierter Angststörung – Voyage
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized Anxiety Disorder - Voyage
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
The study will enroll up to 200 participants aged 18 to 74 years, inclusive with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) confirmed primary diagnosis of GAD and a minimum HAM-A total score of at least 20 at Screening and Baseline without clinically relevant medical or psychiatric history.
The study consists of a 12-week randomized, double-blind, single-dose administration period evaluating DT120 versus placebo, followed by a 40-week extension phase with the opportunity for open-label treatment. During this phase, participants will be monitored and evaluated for potential treatment with DT120 based on pre-specified safety and symptom severity criteria.
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
Arizona
-
Gilbert, Arizona, Vereinigte Staaten, 85234
- Lighthouse Psychiatry
-
Scottsdale, Arizona, Vereinigte Staaten, 85022
- Scottsdale Research Institute
-
-
California
-
La Jolla, California, Vereinigte Staaten, 92037
- Kadima Neuropsychiatry Institute
-
San Francisco, California, Vereinigte Staaten, 94158
- UCSF Department of Neurology
-
Santa Monica, California, Vereinigte Staaten, 90404
- Psychedelic Science Institute
-
-
Colorado
-
Denver, Colorado, Vereinigte Staaten, 80209
- Mountain View
-
-
Florida
-
Jacksonville, Florida, Vereinigte Staaten, 32256
- Clinical Neuroscience Solutions Inc.
-
Lauderhill, Florida, Vereinigte Staaten, 33319
- Segal Trials
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30331
- Atlanta Center for Medical Research
-
Decatur, Georgia, Vereinigte Staaten, 30030
- iResearch Atlanta
-
Savannah, Georgia, Vereinigte Staaten, 31405
- CenExel iResearch, LLC
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60640
- Uptown Research Institute
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02116
- Adams Clinical Boston
-
Watertown, Massachusetts, Vereinigte Staaten, 02472
- Adams Clinical Watertown
-
-
New Jersey
-
Marlton, New Jersey, Vereinigte Staaten, 08053
- Hassman Research Institute
-
-
New York
-
New York, New York, Vereinigte Staaten, 10021
- Spectrum Neuroscience and Treatment Institute
-
New York, New York, Vereinigte Staaten, 10032
- New York State Psychiatric Institute (NYSPI)
-
New York, New York, Vereinigte Staaten, 10029
- Adams Clinical Harlem
-
The Bronx, New York, Vereinigte Staaten, 10461
- Adams Clinical Bronx
-
-
Ohio
-
Cleveland, Ohio, Vereinigte Staaten, 44113
- Cleveland Clinic Lutheran Hospital
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97210
- Summit Headlands LLC
-
-
Pennsylvania
-
Moosic, Pennsylvania, Vereinigte Staaten, 18507
- Scranton Medical Institute
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Adams Clinical Philadelphia
-
-
South Carolina
-
North Charleston, South Carolina, Vereinigte Staaten, 29405
- Coastal Carolina Research Center
-
-
Tennessee
-
Memphis, Tennessee, Vereinigte Staaten, 38119
- Clinical Neuroscience Solutions, Inc.
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78712
- University of Texas at Austin
-
Austin, Texas, Vereinigte Staaten, 78759
- BioBehavioral Research of Austin
-
Austin, Texas, Vereinigte Staaten, 78737
- Austin Clinical Trial Partners
-
Dallas, Texas, Vereinigte Staaten, 75231
- FutureSearch Trials of Dallas, LLC
-
DeSoto, Texas, Vereinigte Staaten, 75115
- Adams Clinical Dallas
-
-
Utah
-
Draper, Utah, Vereinigte Staaten, 84020
- Cedar Clinical Research
-
Orem, Utah, Vereinigte Staaten, 84058
- Inner Space Research
-
-
Vermont
-
Bennington, Vermont, Vereinigte Staaten, 05201
- Memory Clinic Inc.
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98104
- Seattle Neuropsychiatric Treatment Center
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Diagnosis of GAD per DSM-5
- Male or female aged 18 to 74
- HAM-A Total Score ≥20
Exclusion Criteria:
- Certain psychiatric disorders (other than generalized anxiety disorder)
- First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
- Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)
- Any clinically significant unstable illness
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Placebo-Komparator: Arm 1 - Placebo
A substance that is designed to have no therapeutic value |
A substance that is designed to have no therapeutic value |
|
Experimental: Arm 2 - 100µg DT120
A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A) |
A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12
Zeitfenster: Baseline to Week 12
|
The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. |
Baseline to Week 12
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Clinical Global Impression - Improvement (CGI-I) Scale score at each timepoint assessed during the 12-week double-blind period
Zeitfenster: Day 2 to Week 12
|
The CGI-I scale is used to measure the clinician's assessment of how much the participant's illness has improved or worsened relative to Baseline (Visit 2). The CGI-I comprises one item with 7 possible ratings (1-7 points), where a lower score indicates improvement, and a higher score indicates worsening. |
Day 2 to Week 12
|
|
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in Clinical Global Impression - Severity (CGI-S) Scale score
Zeitfenster: Baseline to Week 12
|
The CGI-S scale assesses the clinician's impression of the participant's current severity of illness relative to the clinician's experience with patients who have the same diagnosis. The CGI-S comprises one item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness. |
Baseline to Week 12
|
|
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in Patient Global Impression - Severity (PGI-S) Scale score
Zeitfenster: Baseline to Week 12
|
The PGI scale is the patient-reported outcome (PRO) counterpart to the CGI scale. The PGI-S comprises one participant-completed item with 5 possible ratings (1-5) where a higher score indicates more severe illness. |
Baseline to Week 12
|
|
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - EuroQol-5 Dimensions - 5 Levels (EQ-5D-5L)
Zeitfenster: Baseline to Week 12
|
The EuroQol 5 Dimension 5 Level (EQ-5D-5L) is a self-reported outcome measure used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). |
Baseline to Week 12
|
|
Change from Baseline in the Changes in Sexual Functioning Questionnaire (CSFQ-14) total score at each timepoint assessed during the double-blind period
Zeitfenster: Baseline to Week 12
|
The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning. |
Baseline to Week 12
|
|
Percent of men and women with normal and abnormal sexual functioning at each timepoint assessed during the double-blind period
Zeitfenster: Baseline to Week 12
|
The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning. |
Baseline to Week 12
|
|
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in MADRS total score
Zeitfenster: Baseline to Week 52
|
The MADRS is used to assess depression severity and to detect changes due to antidepressant treatment. The MADRS includes 10 clinician-completed items. Each of the 10 questions is scored with a range of 0-6 points. An item score of 0 indicates item not present or normal, while an item score of 6 indicates severe or continuous presence of the symptoms. The total possible score is 60, and higher scores represent a more severe condition. |
Baseline to Week 52
|
|
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in Clinical Global Impression - Severity (CGI-S) Scale score
Zeitfenster: Baseline to Week 52
|
The CGI-S scale assesses the clinician's impression of the participant's current severity of illness relative to the clinician's experience with patients who have the same diagnosis. The CGI-S comprises one item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness. |
Baseline to Week 52
|
|
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in Patient Global Impression - Severity (PGI-S) Scale score
Zeitfenster: Baseline to Week 52
|
The PGI scale is the patient-reported outcome (PRO) counterpart to the CGI scale. The PGI-S comprises one participant-completed item with 5 possible ratings (1-5) where a higher score indicates more severe illness. |
Baseline to Week 52
|
|
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in WPAI-SHP
Zeitfenster: Baseline to Week 52
|
The WPAI-SHP is a 6-item questionnaire, with a recall period of the past 7 days. The WPAI measures impairments in both paid work and unpaid work. It measures absenteeism, presenteeism as well as impairment in unpaid activity because of the health problem under study. |
Baseline to Week 52
|
|
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in EQ-5D-5L
Zeitfenster: Baseline to Week 52
|
The EuroQol 5 Dimension 5 Level (EQ-5D-5L) is a self-reported outcome measure used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). |
Baseline to Week 52
|
|
Percent men and women with normal and abnormal sexual functioning at each timepoint assessed during the open-label period
Zeitfenster: 40 week open label period
|
The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning. |
40 week open label period
|
|
Change from Baseline in HAM-A total score at Week 8, Week 4, Week 2, and Week 1
Zeitfenster: Week 8, Week 4, Week 2, and Week 1
|
The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. |
Week 8, Week 4, Week 2, and Week 1
|
|
HAM-A response (reduction from Baseline score of ≥50%) at each timepoint assessed during the 12-week double-blind period
Zeitfenster: Baseline to Week 12
|
The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. |
Baseline to Week 12
|
|
HAM-A remission (total score ≤7) at each timepoint assessed during the 12-week double-blind treatment period
Zeitfenster: Baseline to Week 12
|
The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. |
Baseline to Week 12
|
|
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - Montgomery-Åsberg Depression Rating Scale (MADRS) total score
Zeitfenster: Baseline to Week 12
|
The MADRS is used to assess depression severity and to detect changes due to antidepressant treatment. The MADRS includes 10 clinician-completed items. Each of the 10 questions is scored with a range of 0-6 points. An item score of 0 indicates item not present or normal, while an item score of 6 indicates severe or continuous presence of the symptoms. The total possible score is 60, and higher scores represent a more severe condition. |
Baseline to Week 12
|
|
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in -Work Productivity and Activity Impairment Specific Health Problem Questionnaire (WPAI-SHP)
Zeitfenster: Baseline to Week 12
|
The WPAI-SHP is a 6-item questionnaire, with a recall period of the past 7 days. The WPAI measures impairments in both paid work and unpaid work. It measures absenteeism, presenteeism as well as impairment in unpaid activity because of the health problem under study. |
Baseline to Week 12
|
|
Percent of participants requiring one, two, three, four, or five doses of DT120 during the 52-week study (Part A and Part B) as assessed by participants meeting protocol-specified retreatment criteria during the 40-week open-label period
Zeitfenster: Day 1 to Week 52
|
Percent of participants requiring one, two, three, four, or five doses of DT120 during the 52-week study (Part A and Part B) as assessed by participants meeting protocol-specified retreatment criteria during the 40-week open-label period |
Day 1 to Week 52
|
|
Time to first treatment or lack of efficacy in the open-label period (Part B)
Zeitfenster: Day 1 to Week 52
|
Measured as time from first dosing in the Double-blind period to participant meeting HAM-A criteria for re-dose or meeting criteria for lack of efficacy |
Day 1 to Week 52
|
|
Need for DT120 treatment as assessed by the average number of DT120 treatments during the study
Zeitfenster: Day 1 to Week 52
|
Average number of treatments assessed from first dose in the double-blind period through completion of the open label extension. |
Day 1 to Week 52
|
|
HAM-A response (reduction from Baseline score of ≥50%) at each timepoint assessed during the 40-week open-label period
Zeitfenster: 40 week open label period
|
The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. |
40 week open label period
|
|
HAM-A remission (total score ≤7) at each timepoint assessed during the 40-week open-label period
Zeitfenster: 40 week open label period
|
The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. |
40 week open label period
|
|
CSFQ-14 total score at each timepoint assessed during the open-label period
Zeitfenster: 40 week open label period
|
The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning. |
40 week open label period
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- MM120-300
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .